TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30307663

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 30
Study: 30308224

Group type: EXPERIMENTAL
Intervention: Emotion regulation at 20 months of age
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Restriction for health at 20 months of age
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Pressure to eat at 20 months of age
Number of subjects: 723
Study: 30308484

Group type: EXPERIMENTAL
Intervention: Joining parents' bed every night
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Joining parents' bed rarely
Number of subjects: 635

Group type: COMPARATOR
Intervention: Not joining parents' bed
Number of subjects: 635
Study: 30309321

Group type: EXPERIMENTAL
Intervention: Carbapenem-resistant strains (n=43)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Multidrug-resistant strains (n=11)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Carbapenem- and multidrug-resistant strains (n=38)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Strains with clinically relevant beta-lactamases (OXA-101, OXA-2, GES-5)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Strains with aminoglycoside modifying enzymes
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Strains with defective OprD
Number of subjects: 92
Study: 30309342

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) and laboratory evaluations including serum creatinine and albumin-to-creatinine ratio
Number of subjects: 2450

Group type: EXPERIMENTAL
Intervention: Intermediate telephone follow-up at 6 and 18 months
Number of subjects: 2450
Study: 30309472

Group type: EXPERIMENTAL
Intervention: Home fetal heart rate monitoring (FHRM) twice daily with a Doppler monitor and weekly or biweekly fetal echocardiograms.
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Home fetal heart rate monitoring (FHRM) and echocardiograms discontinued after 26 weeks.
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Fetal echocardiograms performed as part of the monitoring protocol.
Number of subjects: 315
Study: 30309758

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: PET complete responders (IHP 2007 criteria)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Non-complete responders (IHP 2007 criteria)
Number of subjects: 1202

Group type: EXPERIMENTAL
Intervention: Complete metabolic responders (Lugano 2014 criteria)
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Non-complete metabolic responders (Lugano 2014 criteria)
Number of subjects: 1202
Study: 30309854

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30309993

Group type: EXPERIMENTAL
Intervention: Own brand cigarette
Number of subjects: 25

Group type: COMPARATOR
Intervention: Flavoured cigar (apple, cream, original, wine)
Number of subjects: 25
Study: 30310267

Group type: EXPERIMENTAL
Intervention: Aflibercept (AF group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ranibizumab with photodynamic therapy (PDT group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ranibizumab (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Switching from ranibizumab to aflibercept
Number of subjects: 30
Study: 30311073

Group type: EXPERIMENTAL
Intervention: HUMAN (manually-adapted target controlled infusion protocol)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: EPSAC (computer-controlled predictive control strategy)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BAYES (computer-controlled Bayesian rule-based optimized control strategy)
Number of subjects: 36

Group type: COMPARATOR
Intervention: HUMAN
Number of subjects: 36

Group type: COMPARATOR
Intervention: EPSAC
Number of subjects: 36

Group type: COMPARATOR
Intervention: BAYES
Number of subjects: 36
Study: 30311792

Group type: EXPERIMENTAL
Intervention: Mass spectrometry techniques to detect Treponema pallidum antigens in urine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 60
Study: 30311822

Group type: EXPERIMENTAL
Intervention: One-on-one meeting with a twelve-step program volunteer
Number of subjects: 72
Study: 30312482

Group type: EXPERIMENTAL
Intervention: CELLEX ECP instrument
Number of subjects: 0

Group type: COMPARATOR
Intervention: UVAR XTS ECP instrument
Number of subjects: 0
Study: 30312541

Group type: EXPERIMENTAL
Intervention: Everolimus-based immunosuppression
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard immunosuppression
Number of subjects: 111
Study: 30312717

Group type: EXPERIMENTAL
Intervention: Salvage low-dose-rate (LDR) brachytherapy
Number of subjects: 92
Study: 30314417

Group type: EXPERIMENTAL
Intervention: Standard behavioral treatment with additional one-on-one self-efficacy enhancement sessions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard behavioral treatment
Number of subjects: 120
Study: 30314835

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable scaffold (BRS) implantation
Number of subjects: 505
Study: 30314962

Group type: EXPERIMENTAL
Intervention: Web-based exercise intervention (8 weeks, individualized, supervised)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Web-based exercise intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 20
Study: 30315349

Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (HDC)
Number of subjects: 3
Study: 30316443

Group type: EXPERIMENTAL
Intervention: Multivariate prediction model for diagnosing adenomyosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Presence of myometrial cysts
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fan-shaped echo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hyperechoic islets
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Globular uterus
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Normal uterine shape
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Thickest/thinnest ratio for uterine wall
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maximum width of the junctional zone in sagittal plane
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Regular appearance of junctional zone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Grade of dysmenorrhea measured on a verbal numerical rating scale
Number of subjects: 100
Study: 30316782

Group type: EXPERIMENTAL
Intervention: Dot app (Dynamic Optimal Timing)
Number of subjects: 718
Study: 30316827

Group type: EXPERIMENTAL
Intervention: NHT plus WPRT
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: NHT plus PORT
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: WPRT plus AHT
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: PORT plus AHT
Number of subjects: 1322
Study: 30316935

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: CT-measured VAT
Number of subjects: 1806

Group type: EXPERIMENTAL
Intervention: None of the adiposity measures
Number of subjects: 1806
Study: 30317494

Group type: EXPERIMENTAL
Intervention: IBD patients (n=46)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Healthy controls (n=20)
Number of subjects: 46
Study: 30317671

Group type: EXPERIMENTAL
Intervention: ixekizumab 160 mg at Week 0, 80 mg every 2 weeks through Week 12, and 80 mg every 4 weeks thereafter up to Week 244
Number of subjects: 13
Study: 30318513

Group type: EXPERIMENTAL
Intervention: ARQ 761 (β-lapachone analogue) at a maximum tolerated dose of 390 mg/m, administered on three schedules (weekly, every other week, 2/3 weeks)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ARQ 761 (β-lapachone analogue)
Number of subjects: 42
Study: 30318516

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + hypofractionated radiotherapy (HFRT)
Number of subjects: 24
Study: 30318646

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) dose
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) trough
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: CYP3A5 loss-of-function alleles
Number of subjects: 1472
Study: 30318722

Group type: EXPERIMENTAL
Intervention: Lithium chloride 1 mM
Number of subjects: 205
Study: 30319397

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for 16 weeks
Number of subjects: 0
Study: 30319400

Group type: EXPERIMENTAL
Intervention: Metronomic four-drug regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30319644

Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Number of subjects: 8
Study: 30319729

Group type: EXPERIMENTAL
Intervention: Nonthermal Pulsed Ultrasound Treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30320204

Group type: EXPERIMENTAL
Intervention: Positioning with the thyroid gland facing the cathode end of the X-ray tube
Number of subjects: 48

Group type: COMPARATOR
Intervention: Positioning with the thyroid gland facing the anode end of the X-ray tube
Number of subjects: 48
Study: 30320410

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 3892

Group type: EXPERIMENTAL
Intervention: Reasons for refusal of ICD implantation
Number of subjects: 3892

Group type: EXPERIMENTAL
Intervention: Factors influencing implant decision
Number of subjects: 3892

Group type: EXPERIMENTAL
Intervention: Country differences in refusal rates
Number of subjects: 3892
Study: 30321257

Group type: EXPERIMENTAL
Intervention: Obesity defined by BMI ≥30 or BF% >25% in men and >35% in women.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Obesity defined by BF% >25% in men and >35% in women.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Higher BF%
Number of subjects: 322

Group type: COMPARATOR
Intervention: Cox proportional hazards models adjusted for various factors including age, sex, diabetes mellitus, cardiovascular disease, estimated glomerular filtration rate, urine protein:creatinine ratio, high-sensitivity C-reactive protein, and use of renin-angiotensin-aldosterone system inhibitors or statins.
Number of subjects: 322
Study: 30321282

Group type: EXPERIMENTAL
Intervention: Successful weight-loss maintainers (WLMs)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normal-weight controls (NCs)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Controls with overweight/obesity (OCs)
Number of subjects: 102
Study: 30321312

Group type: EXPERIMENTAL
Intervention: Skin microbiota analysis in patients with cellulitis
Number of subjects: 58
Study: 30321314

Group type: EXPERIMENTAL
Intervention: Presence of both NNRTI/nucleoside reverse transcriptase inhibitor PDR
Number of subjects: 1557

Group type: EXPERIMENTAL
Intervention: Only NNRTI PDR
Number of subjects: 1557

Group type: EXPERIMENTAL
Intervention: Presence of PDR at 20% threshold
Number of subjects: 1557

Group type: COMPARATOR
Intervention: No PDR
Number of subjects: 1557
Study: 30322817

Group type: EXPERIMENTAL
Intervention: One-view digital breast tomosynthesis
Number of subjects: 14848

Group type: COMPARATOR
Intervention: Two-view digital mammography
Number of subjects: 14848
Study: 30322833

Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 636

Group type: COMPARATOR
Intervention: Gain-framed messages
Number of subjects: 636
Study: 30322836

Group type: EXPERIMENTAL
Intervention: Patients with atrial fibrillation (AF)
Number of subjects: 1800
Study: 30322839

Group type: EXPERIMENTAL
Intervention: mHealth interventions (3 increasingly complex interventions)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: mHealth interventions (2 most complex interventions)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 163
Study: 30323149

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation targeted at the fornix
Number of subjects: 5
Study: 30323658

Group type: EXPERIMENTAL
Intervention: MARA-1 group (hypofractionated radiotherapy): 40 Gy in 16 fractions with a concomitant boost of 4 Gy to breast.
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (standard fractionated radiotherapy): 50.4 Gy in 28 fractions plus a sequential electron boost of 10 Gy in 4 fractions.
Number of subjects: 447

Group type: EXPERIMENTAL
Intervention: MARA-1 group (hypofractionated radiotherapy).
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (standard fractionated radiotherapy).
Number of subjects: 447
Study: 30323863

Group type: EXPERIMENTAL
Intervention: Sublingual allergen immunotherapy (SLIT) with house dust mite (HDM) extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals (non-allergic)
Number of subjects: 0
Study: 30323946

Group type: EXPERIMENTAL
Intervention: Daily activity feedback via smartwatch over a 9-hour period
Number of subjects: 52

Group type: COMPARATOR
Intervention: No activity feedback
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Smartwatch adherence
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Retention rate at 3 months post-discharge
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Completion of outcome measures (EQ-5D-5L, WHODAS, RMI)
Number of subjects: 52
Study: 30324088

Group type: EXPERIMENTAL
Intervention: PGA × BSA
Number of subjects: 0

Group type: COMPARATOR
Intervention: PASI
Number of subjects: 0
Study: 30324541

Group type: EXPERIMENTAL
Intervention: BoNT-A injection
Number of subjects: 468
Study: 30324586

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg bid) with Tamoxifen (60 mg loading dose qd days 10-13, 20 mg qd days 14-26)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg bid) with Anastrozole (1 mg qd days 10-19)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg bid) with Letrozole (2.5 mg qd days 10-38)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Olaparib monotherapy (300 mg bid continuously)
Number of subjects: 79
Study: 30324653

Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method for the ICU
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intensive Care Delirium Screening Checklist
Number of subjects: 74
Study: 30325462

Group type: EXPERIMENTAL
Intervention: Segment 1 (early NREM sleep)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Segment 8 (late NREM sleep)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: First half of the night
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Overall analysis including REM sleep
Number of subjects: 41
Study: 30325463

Group type: EXPERIMENTAL
Intervention: CD4 ≥100 cells/μL
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: CD4 50-99 cells/μL
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: CD4 <50 cells/μL
Number of subjects: 736
Study: 30325534

Group type: EXPERIMENTAL
Intervention: Ixekizumab (160-mg loading dose, 80 mg every 2 weeks for the first 12 weeks, then 80 mg every 4 weeks until Week 52)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ixekizumab retreatment (IXE Q4W for 192 weeks)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Treatment Withdrawal Period (Weeks 52 to 100)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Treatment Withdrawal Period
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Retreatment Period
Number of subjects: 78
Study: 30325779

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with reduced subcutaneous adipose tissue (SAT)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with reduced SAT
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: HIV-infected individuals with increased visceral adipose tissue (VAT)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Non-HIV infected individuals with SAT
Number of subjects: 225

Group type: COMPARATOR
Intervention: Non-HIV infected individuals with VAT
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: HIV group with reduced SAT
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: HIV group with increased VAT
Number of subjects: 225
Study: 30326301

Group type: EXPERIMENTAL
Intervention: Pan-enteric capsule endoscopy (PCE)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PCE
Number of subjects: 46
Study: 30326324

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30326728

Group type: EXPERIMENTAL
Intervention: Brushed nasal cells
Number of subjects: 0
Study: 30326968

Group type: EXPERIMENTAL
Intervention: Centralized clinical data and biological samples collection
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Biological samples (blood, saliva, endoscopic ultrasound-guided fine needle aspiration materials, fine needle biopsy of metastases, and surgically resected tissue)
Number of subjects: 1500
Study: 30327354

Group type: EXPERIMENTAL
Intervention: Ketone Body Infusion
Number of subjects: 0
Study: 30327360

Group type: EXPERIMENTAL
Intervention: Gestational glucose tolerance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 30327405

Group type: EXPERIMENTAL
Intervention: 10-year risk prediction models for total cardiovascular diseases (CVD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-year risk prediction models for all-cause mortality
Number of subjects: 0
Study: 30327597

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y
Number of subjects: 0
Study: 30327598

Group type: EXPERIMENTAL
Intervention: 30-day home-based jigsaw puzzle intervention (≥1 h/day) plus four sessions of cognitive health counseling
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cognitive health counseling only
Number of subjects: 100
Study: 30327612

Group type: EXPERIMENTAL
Intervention: Daily intake of energy
Number of subjects: 1140
Study: 30327731

Group type: EXPERIMENTAL
Intervention: Subacromial injection with 40 mg of Methylprednisolone Acetate and 2 ml of Lidocaine
Number of subjects: 20
Study: 30328062

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) via mid-gut
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Manual preparation of fecal microbiota
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Automatic preparation of fecal microbiota
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Fecal microbiota purification methods
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 139
Study: 30328739

Group type: EXPERIMENTAL
Intervention: Kisspeptin (KP) levels in the UI group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Kisspeptin (KP) levels in the PCOS group
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Kisspeptin (KP) levels in the MFI group
Number of subjects: 86

Group type: COMPARATOR
Intervention: Comparison of KP levels across groups
Number of subjects: 86

Group type: COMPARATOR
Intervention: Diagnostic performance of KP in PCOS
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Potential treatment for UI
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: KP as a marker for AFC and diagnosis of PCOS
Number of subjects: 86
Study: 30328801

Group type: EXPERIMENTAL
Intervention: Electrocardiographic predictors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30328928

Group type: COMPARATOR
Intervention: Normal lung function group (n=147)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Abnormal lung function group (n=58)
Number of subjects: 205
Study: 30328967

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Stretching
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 30333050

Group type: EXPERIMENTAL
Intervention: Oral debriefing
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral debriefing assisted by video
Number of subjects: 24
Study: 30333052

Group type: EXPERIMENTAL
Intervention: Mindfulness and PAP (Physical Activity on Prescription)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Only PAP
Number of subjects: 90

Group type: COMPARATOR
Intervention: Mindfulness only
Number of subjects: 90
Study: 30333122

Group type: EXPERIMENTAL
Intervention: Survival staging system incorporating BNP
Number of subjects: 0
Study: 30333160

Group type: EXPERIMENTAL
Intervention: Cognitive risk score developed from 4 factors (NIH Stroke Scale score on admission ≥7, among others)
Number of subjects: 404
Study: 30333224

Group type: EXPERIMENTAL
Intervention: Cerdulatinib (oral administration, dose-escalation, once-daily or twice-daily schedules)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Cerdulatinib (oral administration)
Number of subjects: 43
Study: 30333303

Group type: EXPERIMENTAL
Intervention: S4injury score
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: S2TCMR score
Number of subjects: 454

Group type: COMPARATOR
Intervention: Histology diagnoses
Number of subjects: 454
Study: 30333794

Group type: EXPERIMENTAL
Intervention: Cardio-Pulmonary Exercise (CPX) testing in individuals with Type 1 Diabetes (T1D)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cardio-Pulmonary Exercise (CPX) testing in healthy individuals (CON)
Number of subjects: 14
Study: 30333892

Group type: EXPERIMENTAL
Intervention: TJ-100
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 30334093

Group type: EXPERIMENTAL
Intervention: Finite element modeling (FE) and computed tomography (CT) measures of bone structure at the knee.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Finite element modeling (FE) measures of stiffness under axial compression and torsional loading.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CT-derived measures of bone mineral density (vBMD) and bone mineral content (BMC).
Number of subjects: 101
Study: 30334147

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study: 30334192

Group type: EXPERIMENTAL
Intervention: Peripheral nerve block (PNB)
Number of subjects: 1623

Group type: COMPARATOR
Intervention: No peripheral nerve block (PNB)
Number of subjects: 1623
Study: 30334263

Group type: EXPERIMENTAL
Intervention: FibroTest in NAFLD
Number of subjects: 1079

Group type: COMPARATOR
Intervention: FibroTest in chronic hepatitis C (CHC)
Number of subjects: 1079

Group type: EXPERIMENTAL
Intervention: Prognostic value of FibroTest in NAFLD
Number of subjects: 1079

Group type: COMPARATOR
Intervention: Prognostic value of FibroTest in CHC
Number of subjects: 1079